Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Eli Lilly and Company LLY

Healthcare — Drug Manufacturers General
S&P 500 Member Dividend Champion (3y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

Eli Lilly and Company (LLY) Business Profile

Company Overview

Eli Lilly and Company (LLY) is a globally recognized pharmaceutical company headquartered in Indianapolis, Indiana, USA. Founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War, the company has a rich history of innovation and commitment to improving human health. Over the years, Eli Lilly has grown into one of the largest pharmaceutical companies in the world, with operations in over 120 countries.

The company is led by a team of experienced executives. As of October 2023, David A. Ricks serves as the Chairman and Chief Executive Officer (CEO). Under his leadership, Eli Lilly has focused on innovation, strategic partnerships, and expanding its global footprint. Other key members of the leadership team include Anat Ashkenazi, the Chief Financial Officer (CFO), and Daniel M. Skovronsky, the Chief Scientific and Medical Officer.

Core Business Segments

Eli Lilly operates across several core business segments, focusing on innovative medicines that address critical health challenges. The company’s product portfolio is divided into the following major categories:

1. Diabetes and Endocrinology

Eli Lilly is a leader in diabetes care, offering a range of products to help manage the condition. Key products in this segment include:

  • Trulicity: A once-weekly injectable medication for type 2 diabetes.
  • Humalog: A fast-acting insulin for diabetes management.
  • Basaglar: A long-acting insulin product.
  • Jardiance: A medication for type 2 diabetes that also reduces the risk of cardiovascular death.

2. Oncology

The oncology segment focuses on treatments for various types of cancer. Key products include:

  • Verzenio: A treatment for advanced breast cancer.
  • Cyramza: A therapy for stomach, lung, and colorectal cancers.
  • Retevmo: A targeted therapy for certain types of lung and thyroid cancers.

3. Immunology

Eli Lilly has developed treatments for autoimmune diseases and other immunological conditions. Key products include:

  • Taltz: A medication for psoriasis and psoriatic arthritis.
  • Olumiant: A treatment for rheumatoid arthritis and alopecia areata.

4. Neuroscience

The neuroscience segment focuses on mental health and neurological disorders. Key products include:

  • Emgality: A preventive treatment for migraines.
  • Zyprexa: A medication for schizophrenia and bipolar disorder.

5. Other Therapeutic Areas

Eli Lilly also offers products in other therapeutic areas, including:

  • Bamlanivimab: A monoclonal antibody treatment for COVID-19.
  • Cialis: A medication for erectile dysfunction and benign prostatic hyperplasia.

Business Model

Eli Lilly’s business model revolves around research and development (R&D), manufacturing, and commercialization of innovative medicines. The company invests heavily in R&D to discover and develop new treatments, spending billions annually to advance its pipeline of drugs. Once a product is developed, Eli Lilly leverages its global manufacturing and distribution network to bring it to market.

Revenue is primarily generated through the sale of prescription medications. The company also collaborates with other pharmaceutical firms and research institutions to co-develop and commercialize products, further diversifying its revenue streams.

Strategic Direction

Eli Lilly’s strategic direction focuses on innovation, sustainability, and global expansion. Key elements of its strategy include:

  • Pipeline Expansion: The company is committed to advancing its pipeline of drugs, with a focus on areas like diabetes, oncology, and neuroscience.
  • Sustainability Goals: Eli Lilly aims to reduce its environmental footprint by adopting sustainable practices in manufacturing and operations. The company has set ambitious goals to achieve carbon neutrality and reduce waste.
  • Digital Transformation: Leveraging digital technologies to enhance R&D, improve patient outcomes, and streamline operations.
  • Global Growth: Expanding its presence in emerging markets to reach more patients and drive revenue growth.

Competitive Landscape

Eli Lilly operates in a highly competitive pharmaceutical industry. Key competitors include:

  • Pfizer: Known for its broad portfolio of medicines and vaccines.
  • Merck & Co.: A leader in oncology and vaccines.
  • Novo Nordisk: A major competitor in the diabetes care segment.
  • Bristol-Myers Squibb: Focused on oncology, immunology, and cardiovascular diseases.
  • Johnson & Johnson: A diversified healthcare company with a strong pharmaceutical division.

Risk Factors

Eli Lilly faces several risks that could impact its business:

  • Regulatory Risks: The pharmaceutical industry is heavily regulated, and changes in regulations could affect product approvals and operations.
  • Market Dependence: Reliance on a few key products for a significant portion of revenue.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing could impact product availability.
  • Patent Expirations: Loss of patent protection for key products could lead to increased competition from generics.
  • Litigation Risks: Exposure to lawsuits related to product safety or marketing practices.

Recent Developments

Eli Lilly has made significant strides in recent years. Notable developments include:

  • New Product Approvals: The FDA recently approved Mounjaro, a novel treatment for type 2 diabetes.
  • COVID-19 Response: Development of monoclonal antibody treatments like Bamlanivimab to combat COVID-19.
  • Acquisitions: Strategic acquisitions to bolster its pipeline and expand into new therapeutic areas.
  • Global Expansion: Opening new manufacturing facilities in emerging markets to meet growing demand.

Investment Considerations

Strengths:

  • Strong pipeline of innovative drugs.
  • Leadership position in diabetes and oncology.
  • Robust financial performance and cash flow.
  • Commitment to sustainability and digital transformation.

Risks:

  • Dependence on a few key products for revenue.
  • Exposure to regulatory and litigation risks.
  • Competitive pressures from other pharmaceutical companies.

Conclusion

Eli Lilly and Company is a global leader in the pharmaceutical industry, known for its innovative medicines and commitment to improving human health. With a strong pipeline, strategic focus on sustainability, and a robust global presence, the company is well-positioned for future growth. However, investors should consider the risks associated with regulatory challenges, market dependence, and competition. Overall, Eli Lilly remains a compelling player in the healthcare sector, with significant potential for long-term success.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us